Clinical Trial

H1 Boosts Flagship Clinical Trial Intelligence Platform with Generative AI to Accelerate Clinical Trials

Seamlessly nestled within Trial Landscape, GenosAI™ enables pharma to look across vast data sets, simplify complex queries, and accelerate clinical…

6 months ago

Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

COPENHAGEN, Denmark, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology…

6 months ago

SeaStar Medical to Present at the Dawson James Small Cap Growth Conference on October 12, 2023

DENVER, Oct. 05, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions…

6 months ago

Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™

– Resubmission follows the satisfactory resolution of the FDA’s review of inspection findings at the third-party filler – REDWOOD CITY, Calif.,…

6 months ago

Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

TN-201 is the First Gene Therapy for the Leading Genetic Cause of HCM to be Assessed in Humans; Adds Working…

6 months ago

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes

BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 1…

6 months ago

MediOrbisTM Partners with INTERVENT International to Offer Proven Health Risk Management, Longitudinal Care and Medical Weight Loss Services

CLEVELAND, OH / ACCESSWIRE / October 4, 2023 / MediOrbis, a global multi-specialty telehealth company with comprehensive specialty telemedicine services…

6 months ago

AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance

 Fiscal Year 2024 First Quarter Highlights Net sales of $78.7 million as reported Includes $0.7 million of Dialysis and BioSentry…

6 months ago

FloraWorks Appoints Cannabis Scientist Dr. Mike McCormick as VP of Strategy

Portland, Oregon--(Newsfile Corp. - October 4, 2023) - FloraWorks Holdings Inc., a leading cannabinoid therapeutics company, announced the appointment of Dr.…

6 months ago